American Statistical Association
Neuroblastoma is the most common extracranial solid tumor in children. It accounts for 5% of all pediatric tumor diagnosis but is responsible for 10% of pediatric cancer mortality. The median age of diagnosis is 17 months and importantly 2 in 3 children present with metastatic disease. MYC-N amplification is associated with high-risk disease, metastasis and poor survival (< 40%). Studies aimed towards a better understanding of high-risk neuroblastoma biology, disease progression, gene-treatment interactions and novel therapeutic targets are desperately needed. A brief overview of recent insights from cancer genomics will be presented followed by some early insights into neuroblastoma pathogenesis, disease progression and metastasis using comprehensive whole genome sequencing analysis.
|Date:||Wednesday, December 14, 2016|
|Time:||4:00 - 5:00 P.M.|
Memorial Sloan Kettering Cancer Center
Department of Epidemiology and Biostatistics
485 Lexington Avenue
(Between 46th & 47th Streets)
Conference Room C
New York, New York
**Outside visitors please email Tania at email@example.com for building access.
You must be on the security list to enter the floor.